Quanterix' proprietary Simoa Bead Technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.
Videos and Recordings
Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing
In an excerpt from a panel discussion which took place at MedCity CONVERGE on July 11, 2018, Quanterix Chairman and CEO Kevin Hrusovsky joins other key innovators to discuss game-changing biotech advancements and the future of healthcare.
Disrupting Drug Development with Biomarkers and the Power of Precision Health
This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts.
President, CEO & Chairman of Quanterix
We're passionate about the work we do and believe we can transform today’s sick care into tomorrow’s precision healthcare.